2012: Year in review
Recent articles
What stood out to you in 2012?
We packaged the year’s research highlights from our vantage point. What advances stood out to you in 2012? And where do you see the field going?
What stood out to you in 2012?
We packaged the year’s research highlights from our vantage point. What advances stood out to you in 2012? And where do you see the field going?
Top tools and techniques of 2012
2012 saw many new exciting — and often colorful — technical advances, ranging from tools that build brains from the cell up to robots that can replace neuroscientists.
Top tools and techniques of 2012
2012 saw many new exciting — and often colorful — technical advances, ranging from tools that build brains from the cell up to robots that can replace neuroscientists.
Drugs in development for autism
A look at various drugs attempting to address autism and their stages of development.
Drugs in development for autism
A look at various drugs attempting to address autism and their stages of development.
Predictions for 2013
Take a look through SFARI.org’s crystal ball to predict major developments in autism research in 2013.
Predictions for 2013
Take a look through SFARI.org’s crystal ball to predict major developments in autism research in 2013.
Most-viewed articles of 2012
A list of the ten stories that most caught our readers’ attention this year.
Most-viewed articles of 2012
A list of the ten stories that most caught our readers’ attention this year.
Hot topics in 2012
New candidate genes, drugs in development and diagnostic debates were just a few of the themes that garnered intense interest this year.
Hot topics in 2012
New candidate genes, drugs in development and diagnostic debates were just a few of the themes that garnered intense interest this year.
Director’s column: 2012 in review
SFARI director Gerald Fischbach comments on the year’s most notable papers.
Director’s column: 2012 in review
SFARI director Gerald Fischbach comments on the year’s most notable papers.
Notable papers of 2012
Among a wealth of exciting research, ten sets of papers made an impact this year.
Notable papers of 2012
Among a wealth of exciting research, ten sets of papers made an impact this year.
Explore more from The Transmitter
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
‘Overdue’ debate unfurls over neuroimaging method
After a January paper questioned the validity of an approach called lesion network mapping, its users are pressure testing their results.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
Nearly 400 compounds affect behaviors tied to autism-linked genes in zebrafish
Estropipate, paclitaxel and levocarnitine altered behaviors tied to SCN2A and DYRK1A variants specifically, a new open-source platform revealed.
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”
What neuroscientists want from a new NINDS director
The search is underway for the next director of the U.S. National Institute of Neurological Disorders and Stroke, who will face a range of challenges, neuroscientists say, but will also have an “immense opportunity to do good things.”